(AOF) – Bristol Myers Squibb announced the acquisition of the American biotech Mirati for $58.00 per share, representing a net value of $4.8 billion and up to $5.8 billion, while it Sanofi was expected to take over the company at the end of last week. The acquisition notably brings Mirati’s flagship product, called Krazati (adagrasib), approved by the FDA for the treatment of certain lung cancers.
“With a strong strategic fit, high-level science and clear opportunities to create value for our shareholders, the Mirati transaction is aligned with our business development objectives,” says Giovanni Caforio, Chief Executive Officer and Chairman of the Board. by Bristol Myers Squibb.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
